RxDoctor Payments Data

Holly Jackson, NP

Family · Carrollton, GANPI 1427576511

Payments from drug & device makers

$318in general payments, 2019–2025

Across 15 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$106
  • Novo Nordisk$43
  • Axsome Therapeutics, Inc.$32
  • Lilly USA, LLC$31
  • Boston Scientific$23
  • Sanofi Pasteur Inc.$20
  • plus $63 from 4 others

What the payments were for

  • Food & beverage$30596%
  • Other$134%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$318 in reported general payments places this provider in the 45th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$40,492
Medicare patients
131
Services billed
1,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide230$270,065
JardianceEmpagliflozin58$70,784
Soliqua 100-33Insulin Glargine/Lixisenatide74$68,733
EliquisApixaban58$64,314
MounjaroTirzepatide59$59,743
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$50,177
LinzessLinaclotide39$29,122
Tresiba Flextouch U-200Insulin Degludec21$26,777
MyrbetriqMirabegron31$24,458
TrulicityDulaglutide21$22,590
Repatha SureclickEvolocumab28$22,451
BrilintaTicagrelor14$14,141
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$13,138
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$10,679
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$43$270,065230 claims
Lilly USA, LLCMounjaro, Trulicity$31$82,33480 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$106$70,33387 claims
PfizerEliquis$16$64,31458 claims
GSKTrelegy Ellipta, Anoro Ellipta$18$60,85583 claims
AbbVieLinzess, Synthroid$16$30,63853 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 6,258 family providers in Georgia.

Other family in Carrollton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →